Table 4. Median (IQR) exposure in... | American Society of Hematology

Table 4.

Median (IQR) exposure in subjects with extended dosing interval (14 or more days at any time) (subanalysis 2)

	Before the first ≥14-day dosing interval	During the ≥14-day dosing interval
Exposure period,∗ d	n = 22	n = 23
	122.1 (61.0-269.0)	1565.2 (647.8-1766.7)
Exposure d∗	n = 22	n = 23
	12.5 (6.0-22.0)	113.0 (69.0-139.0)
Dosing interval,† d	n = 20	n = 23
	11.0 (10.0- 12.0)	14.0 (14.0-14.0)
Weekly dose,‡ IU/kg	n = 20	n = 23
	62.5 (59.0-71.3)	50.0 (45.6-51.0)

	Before the first ≥14-day dosing interval	During the ≥14-day dosing interval
Exposure period,∗ d	n = 22	n = 23
	122.1 (61.0-269.0)	1565.2 (647.8-1766.7)
Exposure d∗	n = 22	n = 23
	12.5 (6.0-22.0)	113.0 (69.0-139.0)
Dosing interval,† d	n = 20	n = 23
	11.0 (10.0- 12.0)	14.0 (14.0-14.0)
Weekly dose,‡ IU/kg	n = 20	n = 23
	62.5 (59.0-71.3)	50.0 (45.6-51.0)

Based on all prior dosing intervals.

Based on the latest prior prescribed dosing interval, excluding subjects with an on-demand regimen directly before the ≥14-day dosing.

Based on the latest prior dosing interval, excluding subjects with an on-demand regimen directly before the ≥14-day dosing.